All Releases
 |
Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™
May 21, 2013
|
19.8 KB |
|
| |
Aradigm's Proprietary Inhaled Ciprofloxacin Formulation is a
Potential New Therapy for Patients with Severe Respiratory Disease
BARCELONA, Spain & HAYWARD, Calif.--(BUSINESS WIRE)--
Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) ("Grifols") and
Aradigm Corporation (OTC BB:ARDM.OB) ("Arad...
|
|
Aradigm Announces First Quarter 2013 Financial Results
May 14, 2013
|
18.6 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB: ARDM.OB) (the "Company") today
announced financial results for the first quarter and three months ended
March 31, 2013.
Total revenue was $0.3 million for the first quarter of 2013, compared
with $0.3 million in revenue for th...
|
|
Aradigm Announces Fourth Quarter 2012 and Full Year Financial Results
Mar 26, 2013
|
26.2 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today
announced financial results for the fourth quarter and full year ended
December 31, 2012.
Fourth Quarter 2012 Results
The Company recorded $223,000 in revenue in the fourth quart...
|
|
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2013 on February 12
Feb 6, 2013
|
11.6 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
President and Chief Executive Officer, Igor Gonda, Ph.D., will present
at the 15th Annual BIO CEO & Investor Conference 2013 on
Tuesday, February 12, 2013, at 2:00 p.m. ET. The event will be held at
t...
|
|
Aradigm to Present at Biotech Showcase 2013 on January 9
Jan 3, 2013
|
11.5 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
President and Chief Executive Officer, Igor Gonda, Ph.D., will present
at Biotech Showcase 2013 on Wednesday, January 9, 2013, at 11: 00 a.m.
Pacific time. The event will be held at Parc 55 Wyndham — Uni...
|
|
Aradigm Announces Private Placement for $6 Million
Dec 12, 2012
|
14.3 KB |
|
| |
Proceeds Will Further Development of Inhaled Ciprofloxacin for the
Treatment of Severe Respiratory Diseases
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it
has entered into a definitive agreement for the sale of common stock to
...
|
|
UK Scientists Report on Efficacy of Aradigm's Lipoquin™ Against Pneumonic Plague
Nov 19, 2012
|
16.0 KB |
|
| |
A Single Dose of Aradigm's Liposomal Ciprofloxacin Delivered 24 Hours
Post-Exposure with a Lethal Dose of Plague Provided Full Protection
HAYWARD, Calif.--(BUSINESS WIRE)--
Scientists from the UK Defence Science and Technology Laboratory (Dstl)
report, in a preliminary study, that they have ...
|
|
Aradigm Announces Third Quarter 2012 Financial Results
Nov 8, 2012
|
61.1 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today
announced financial results for the third quarter and nine months ended
September 30, 2012.
Total revenue was approximately $0.3 million for the third quarter of
2012 compared with revenue of ap...
|
|
Virginia Commonwealth University Scientists Report Anti-Inflammatory Effect of Aradigm's Inhaled Liposomal Ciprofloxacin
Oct 16, 2012
|
52.2 KB |
|
| |
Major Inflammation Stimulating Factor Produced During Serious Lung
Infections Inhibited by Aradigm's Drug
HAYWARD, Calif.--(BUSINESS WIRE)--
Today at the annual meeting of the American Association of
Pharmaceutical Scientists (AAPS) in Chicago, IL, scientists from the
Virginia Commo...
|
|
UK Scientists Report Successful Testing of Aradigm's Inhaled Liposomal Ciprofloxacin in Q Fever
Sep 20, 2012
|
15.0 KB |
|
| |
Q Fever is a Highly Infectious and Life Threatening Infection
HAYWARD, Calif.--(BUSINESS WIRE)--
UK scientists from the Health Protection Agency (HPA) and Defence
Science and Technology Laboratory (Dstl) reported this week at the
University of Southampton's Wessex Life Sciences Alliance Conf...
|
|
New U.S. Composition of Matter Patent for Aradigm's Pulmaquin™ and Lipoquin™ Provides Protection Until 2031
Sep 18, 2012
|
14.1 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB: ARDM) ("Aradigm" or the "Company") today
announced that the United States Patent and Trademark Office has issued
an important new composition of matter patent (U.S. Patent No.
8,268,347) to Aradigm for formulations of liposomal and free
cipro...
|
|
Aradigm Patent Protection for Smoking Cessation is Extended with Issuance of a Method of Treatment Patent
Sep 5, 2012
|
13.3 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB: ARDM) ("Aradigm" or the "Company") today
announced that the United States Patent and Trademark Office has issued
an important method of treatment patent (U.S. Patent No. 8,256,433)
covering Systems and Methods for Effecting Cessation of Tobacco Use. T...
|
|
Aradigm to Participate in FDA Workshop on Non-Cystic Fibrosis Bronchiectasis
Aug 30, 2012
|
11.7 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
Igor Gonda, PhD., Aradigm's President and CEO, will be a panel member at
the U.S. Food and Drug Administration's public workshop regarding the
design of clinical trials of antibacterial drugs for the treatment...
|
|
Aradigm to Present at the Stifel Nicolaus 2012 Healthcare Conference
Aug 29, 2012
|
11.5 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
Nancy E. Pecota, Aradigm's Vice President, Finance and Chief Financial
Officer, will present an overview of the Company at the Stifel Nicolaus
2012 Healthcare Conference at the Four Seasons Hotel in Boston on
...
|
|
Aradigm Announces Second Quarter 2012 Financial Results
Aug 9, 2012
|
19.6 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today
announced financial results for the second quarter and six months ended
June 30, 2012.
Total revenue was approximately $0.2 million for both the second quarter
of 2012 and the second quarter of ...
|
|
Aradigm Announces First Quarter 2012 Financial Results
May 11, 2012
|
18.8 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTC BB:ARDM.OB) (the "Company") today
announced financial results for the first quarter and three months ended
March 31, 2012.
Total revenue was $0.3 million for the first quarter of 2012, compared
with $0.2 million in revenue for th...
|
|
Aradigm Announces Fourth Quarter 2011 and Full Year Financial Results
Mar 27, 2012
|
25.7 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today
announced financial results for the fourth quarter and full year ended
December 31, 2011.
The Company recorded $183,000 in revenue in the fourth quarter of 2011
compared with $144,000 in revenue in t...
|
|
Aradigm Receives U.S. FDA Clearance for Phase 3 Clinical Trial of Pulmaquin™ in Patients with Non-Cystic Fibrosis Bronchiectasis
Mar 12, 2012
|
14.2 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or the "Company") today
announced that the Company's Investigational New Drug Application (IND)
to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release
ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis ...
|
|
US Patent Protection for Pulmaquin™ Is Extended with Issuance of a Composition of Matter Patent
Feb 21, 2012
|
14.4 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB: ARDM) ("Aradigm" or the "Company") today
announced that the United States Patent and Trademark Office has issued
an important composition of matter patent (U.S. Patent No. 8,119,156)
covering formulations of liposomal and free ciprofloxacin, including...
|
|
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2012 on February 13
Feb 8, 2012
|
11.5 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
President and Chief Executive Officer, Igor Gonda, Ph.D., will present
at the 14th Annual BIO CEO & Investor Conference 2012 on
Monday, February 13, 2012, at 2:30 p.m. ET. The event will be held at
th...
|
|
|
Press Releasese
